INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 223 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $3,000 | -25.0% | 597 | 0.0% | 0.00% | – |
Q3 2021 | $4,000 | -33.3% | 597 | 0.0% | 0.00% | – |
Q2 2021 | $6,000 | 0.0% | 597 | 0.0% | 0.00% | – |
Q1 2021 | $6,000 | -70.0% | 597 | -73.8% | 0.00% | -100.0% |
Q4 2020 | $20,000 | -64.9% | 2,277 | -53.6% | 0.00% | 0.0% |
Q3 2020 | $57,000 | -58.4% | 4,911 | -2.6% | 0.00% | -55.6% |
Q2 2020 | $137,000 | +2640.0% | 5,042 | +540.7% | 0.01% | – |
Q1 2020 | $5,000 | -72.2% | 787 | -84.0% | 0.00% | -100.0% |
Q1 2019 | $18,000 | -69.5% | 4,933 | -66.5% | 0.00% | -80.0% |
Q4 2018 | $59,000 | +353.8% | 14,718 | +522.6% | 0.01% | +400.0% |
Q3 2018 | $13,000 | -99.3% | 2,364 | +404.1% | 0.00% | – |
Q2 2018 | $1,838,000 | +183700.0% | 469 | +189.5% | 0.00% | – |
Q1 2018 | $1,000 | -50.0% | 162 | -69.7% | 0.00% | – |
Q4 2017 | $2,000 | -50.0% | 534 | -23.5% | 0.00% | – |
Q3 2017 | $4,000 | -60.0% | 698 | -45.8% | 0.00% | -100.0% |
Q2 2017 | $10,000 | +11.1% | 1,289 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $9,000 | +80.0% | 1,289 | +62.8% | 0.00% | – |
Q4 2016 | $5,000 | – | 792 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
Beck Bode, LLC | 41,218 | $33,799 | 0.01% |